

**Targeted inhibition of the *Plasmodium falciparum*
Vitamin B6 producing enzyme Pdx1 and the
biochemical and functional consequences thereof**

Shaun Bernard Reeksting

Submitted in partial fulfilment of the requirements for the degree

Philosophiae Doctor

in the Faculty of Natural and Agricultural Sciences

Department of Biochemistry

University of Pretoria

South Africa

June 2013

Submission declaration

I, Shaun Bernard Reeksting, declare that this thesis, which I hereby submit for the degree *Philosophiae Doctor* in the Department of Biochemistry, at the University of Pretoria, is my own work and has not previously been submitted by me for a degree at this or any other tertiary institution.

Signature:

Date:

Plagiarism declaration

I understand what plagiarism is and am aware of the University's policy in this regard.

I declare that this thesis is my own original work. Where other people's work has been used (either from printed source, internet or any other source), this has been properly acknowledged and referenced in accordance with departmental regulations.

I have not used work previously produced by another student or any other person to hand in as my own.

I have not allowed and will not allow anyone to copy my work with the intention of passing it off as his or her own work.

Student's signature

Date

Summary

Malaria is caused by the parasite *Plasmodium falciparum* and still plagues many parts of the world. To date, efforts to control the spread of the parasites have been largely ineffective. Due to development of resistance by the parasites to current therapeutics there is an urgent need for new classes of therapeutics. The vitamin B₆ biosynthetic pathway consists of a PLP synthase which produces pyridoxal 5'-phosphate (PLP) within the parasite. The absence of this pathway in humans makes it attractive for selective targeting using small chemical molecules. The PLP synthase condenses D-ribose 5-phosphate (R5P) and DL-glyceraldehyde 3-phosphate (G3P) with ammonia to form PLP. Two proteins make up this PLP synthase – *PfPdx1* and *PfPdx2*. Computational modelling of *PfPdx1*, and mapping of the R5P-binding site pharmacophore facilitated the identification of several ligands with predicted favourable binding interactions. Confirmatory testing of these on the purified *PfPdx1* *in vitro* revealed D-erythrose 4-phosphate (E4P) and an analogue 4-phospho-D-erythronhydrazide (4PEHz) were capable of dose-dependently inhibiting the enzyme. The acyclic tetrose scaffold of E4P, with both aldehyde and phosphate group moieties, was thought to affect R5P imine bond formation in *PfPdx1*, possibly allowing the molecule to enter the R5P-binding site of *PfPdx1*. This hypothesis was supported by molecular docking simulations, and suggested that 4PEHz could similarly enter the R5P-binding site. 4PEHz was detrimental to the proliferation of cultured *P. falciparum* intraerythrocytic parasites and had an inhibitory concentration (IC₅₀) of 10 μM. The selectivity of 4PEHz in targeting *PfPdx1* was investigated using transgenic cell lines over-expressing *PfPdx1* and *PfPdx2*, revealing that complementation of PLP biosynthesis rescued the parasites from the detrimental effects of 4PEHz. Functional transcriptomic and proteomic characterisation of 4PEHz-treated parasites revealed that the expression of *PfPdx2* increased during 4PEHz treatment, moreover showed that other PLP-related processes were affected. These results supported that *PfPdx1* is targeted by 4PEHz, and affected PLP biosynthesis *de novo*. Results from this study allude to alternative regulation of *de novo* PLP biosynthesis within the parasites by E4P. Moreover, contributions from this work showed that the *de novo* vitamin B₆ pathway of *P. falciparum* is chemically targetable, and a potential strategy for the development of newer antimalarials.

Abbreviations

4PEHz	4-phospho-D-erythronhydrazide
ACT	artemisinin combinational therapeutics
ALAS	delta-aminolevulinic acid synthetase (ALAS)
ANCOVA	analysis of covariance
AspAT	aspartate aminotransferase or aspartate transaminase
ATP	adenosine triphosphate
BNI	Bernhard-Nocht Institute for Tropical Medicine
<i>BsPdx1</i>	<i>Bacillus subtilis</i> Pdx1
CDC	Centers for Disease Control
CPS	carbamoyl phosphate synthetases
CQ	chloroquine
CS	circumsporozoite
Cyc	cyclophillin
DDT	dichlorodiphenyltrichloroethane
DHA	dihydroartemisinin
DHAP	dihydroxyacetone phosphate
DHFR-TS	dihydrofolate reductase-thymidylate synthase
DHPS	dihydropteroate synthase
DOPE	discrete optimized protein energy
DS	Discovery Studio
DXP	deoxy-D-xylulose 5-phosphate
E4P	D-erythrose 4-phosphate
FC	fold change
F6P	D-fructose 6-phosphate
G3P	DL-glyceraldehyde 3-phosphate
GMAP	Global Malaria Action Plan
GO	Gene ontology
GSEA	Gene set enrichment analysis
Hb	haemoglobin
HEPES	4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
HDAC	histone deactelyase
HPI	hours post invasion

HTS	high-throughput screening
IDC	intra-erythrocytic development cycle
IRS	indoor residual spraying
ITN	insecticide treated bed nets
KEGG	Kyoto encyclopaedia of genes and genomes
LDH	Lactate dehydrogenase
LLIN	long lasting impregnated nets
LPM	ligand pharmacophore mapping
MMV	The Medicines for Malaria Venture
MSA	multiple protein sequence alignment
MPD	(4 <i>S</i>)-2-methyl-2,4-pentanediol
OAT	L-ornithine aminotransferase
ODC	L-ornithine decarboxylase
PABA	<i>p</i> -aminobenzoic acid
PAGE	polyacrylamide gel electrophoresis
<i>Pb</i> Pdx1	<i>Plasmodium berghei</i> Pdx1
<i>Pf</i> Pdx1	<i>Plasmodium falciparum</i> Pdx1
<i>Pf</i> Pdx2	<i>Plasmodium falciparum</i> Pdx2
PCR	polymerase chain reactions
PDF	probability density function
Pdx1	SNO glutamine amidotransferase family protein
Pdx2	SNO glutamine amidotransferase family protein
PdxK	pyridoxine kinases
PdxP	pyridoxal phosphatases
PfCRT	chloroquine resistance transporter
<i>Pf</i> MDR	multidrug resistance transporter 1
PL	pyridoxal
PLP	pyridoxal 5'-phosphate
PM	pyridoxamine
PN	pyridoxine
PNPase	4-nitrophenyl phosphatase
PMSF	phenylmethylsulphonyl fluoride
PPP	pentose phosphate pathway
PQ	primaquine

PS	phosphatidylserine
PSDC	phosphatidylserine decarboxylase
RBM	Roll Back Malaria Partnership
RMSD	root mean square deviation
RQI	RNA quality indicator
rRNA	ribosomal RNAs
R5P	D-ribose 5-phosphate
Ru5P	D-ribulose-5-phosphate
SAR	structure activity relationship
SCD	sickle cell disease
<i>ScPdx1</i>	<i>Sacchromyces cerevisiae</i> Pdx1
SDS	Sodium dodecyl sulphate
SHMT	serine hydroxymethyltransferase
SP	sulpha doxine-pyrimethamin
SPT	serine C-palmitoyltransferase
STRING	Search Tool for the Retrieval of Interacting Genes/Proteins
StSyn	seryl-tRNA synthetase
T	Treated
THF	tetrahydrofolate
TIM	triosephosphate isomerases
<i>TmPdx2</i>	<i>Thermotoga maritima</i> Pdx1
TPP	thiamine pyrophosphate
<i>TtPdx1</i>	<i>Thermus thermophilus</i> Pdx1
UNICEF	United Nations Children's Fund
UT	Untreated
WHO	World Health Organization
WT	wildtype

Table of Contents

Summary	iv
Abbreviations.....	v
Table of Contents.....	viii
List of Figures	xi
List of Tables.....	xiii
Acknowledgements.....	xiv
Chapter 1.....	1
1.1 Epidemiology of malaria.....	1
1.1.1 Emergence and history	1
1.1.2 Transmission.....	2
1.1.3 Life cycle of <i>P. falciparum</i> parasites	3
1.1.4 Pathogenesis and clinical features	5
1.1.5 Distribution	5
1.1.6 Incidence rates (frequency)	6
1.2 Control and treatment strategies	7
1.2.1 Vaccines.....	8
1.2.2 Vector control	9
1.2.3 Therapeutics	9
1.3 The significance of vitamin B ₆	16
1.3.1 Vitamin B ₆ metabolism	17
1.3.2 Vitamin B ₆ in the erythrocyte.....	19
1.3.3 Vitamin B ₆ metabolism in the malaria parasite	19
1.3.4 Vitamin B ₆ biosynthesis in <i>P. falciparum</i> as drug target.....	22
1.4 Hypothesis, research objective and aims.....	24
1.5 Outputs.....	25
Chapter 2.....	26
2.1 Introduction	26
2.1.1 Drug discovery	26
2.1.2 The Pdx1 component of PLP synthase	29
2.2 Methods.....	32
2.2.1 Homology modelling	32
2.2.2 Protein minimisation.....	32
2.2.3 Interaction generation.....	33

2.2.4	Pharmacophore clustering	33
2.2.5	Database searching and ligand pharmacophore mapping (LPM).....	34
2.2.6	Docking.....	34
2.3	Results	36
2.3.1	Alignments and template selection	36
2.3.2	Homology modelling of <i>PfPdx1</i>	38
2.3.3	Protein minimisation.....	44
2.3.4	Interaction generation and pharmacophore extraction	50
2.3.5	Database searching and ligand pharmacophore mapping (LPM).....	53
2.3.6	Docking.....	60
2.4	Discussion.....	67
2.5	Conclusions	73
Chapter 3.....		74
3.1.	Introduction	74
3.2.	Methods	78
3.2.1.	Expression and purification of <i>PfPdx1</i>	78
3.2.2.	<i>PfPdx1</i> activity assays and inhibitor preparation	80
3.2.3.	Mutagenesis of <i>PfPdx1</i>	81
3.2.3.1.	Deletion mutagenesis PCR of <i>PfPdx1</i> (<i>PfPdx1</i> Δ ₂₇₀₋₃₀₁)	81
3.2.3.2.	Site-directed point mutation of R164 in <i>PfPdx1</i>	82
3.2.4.	General molecular cloning techniques	82
3.2.4.1.	Purification of PCR and digested fragments	82
3.2.4.2.	Agarose gel electrophoresis	82
3.2.4.3.	Restriction enzyme (RE) digestion.....	82
3.2.4.4.	Ligation	83
3.2.4.5.	Plasmid isolation.....	83
3.3.	Results	88
3.3.1.	Expression of <i>PfPdx1</i> and initial inhibitor screening	88
3.3.2.	The inhibition of <i>PfPdx1</i> by DR5P, and the effects of related analogues	93
3.3.3.	Erythrose 4-phosphate inhibits <i>PfPdx1</i>	95
3.3.4.	Characterisation of R5P-I ₃₂₀ forming residues.....	97
3.3.5.	E4P analogues and their effect on <i>PfPdx1</i>	99
3.3.6.	4PEHz and EHz affect parasite growth	101
3.4.	Discussion.....	105
3.4.1.	<i>PfPdx1</i> pharmacophore-based ligands.....	105
3.4.2.	Substrate preference of <i>PfPdx1</i>	106
3.4.3.	Mutagenesis of <i>PfPdx1</i>	110
3.5.	Conclusions	111
Chapter 4.....		112
4.1	Introduction	112

4.1.1	Transcriptomics in the malaria parasite.....	112
4.2	Methods.....	115
4.2.1	Parasite culturing and drug treatment.....	115
4.2.2	Transcriptomics.....	115
4.2.2.1	RNA isolation.....	115
4.2.2.2	Assessment of RNA purity and quality	116
4.2.2.3	cDNA synthesis	117
4.2.2.4	cDNA labelling.....	118
4.2.2.5	Sample fragmentation and slide oligonucleotide hybridization.....	118
4.2.2.6	Hybridization clean-up	119
4.2.2.7	Data processing.....	119
4.2.2.8	Real-time quantitative RT-PCR (qRT-PCR)	122
4.2.3	Proteomics.....	123
4.2.3.1	Protein extraction.....	123
4.2.3.2	Polyacrylamide gel electrophoresis.....	124
4.2.3.3	MS Proteomics.....	124
4.3	Results	125
4.3.1	Transcriptomics.....	125
4.3.1.1	RNA integrity.....	125
4.3.1.2	Hybridization and raw image processing.....	126
4.3.1.3	Normalisation of microarray image data.....	127
4.3.2	Pearson correlations between UT and T samples	130
4.3.3	Differentially expressed transcripts.....	131
4.3.4	Gene ontology (GO) and functional annotation	135
4.3.5	PLP synthase and PLP-related perturbations.....	138
4.3.6	Comparison to other transcriptomes.....	145
4.3.7	Validation of microarrays using real-time PCR.....	151
4.3.8	Proteome analysis	152
4.3.9	Interaction networks	154
4.4	Discussion.....	157
4.5	Conclusions	166
Chapter 5.....		167
References		173

List of Figures

Figure 1.1: The life cycle of <i>P. falciparum</i>	4
Figure 1.2: The spatial distribution of <i>P. falciparum</i> endemicity in 2010.....	7
Figure 1.3: Different physiological forms of vitamin B ₆	17
Figure 1.4: Summary of vitamin B ₆ biosynthesis and salvage.....	18
Figure 1.5: Erythrocyte and <i>P. falciparum</i> B ₆ homeostasis.....	21
Figure 2.1: Workflow for the identification of ligands from a structure-based pharmacophore. .	28
Figure 2.2: The heterodimeric structure of <i>T. maritima</i> PLP synthase (PDB: 2ISS).....	29
Figure 2.3: Stereoview of the <i>TmPdx1</i> R5P-active site.	31
Figure 2.4: Multiple protein sequence alignment (MSA) generated for Pdx1 homologues.	36
Figure 2.5: Secondary structure topology diagrams of A) <i>TmPdx1</i> and B) <i>TtPdx1</i>	37
Figure 2.6: Comparison of <i>TtPdx1</i> (PDB: 2ZBT) to <i>TmPdx1</i> (PDB: 2ISS).....	38
Figure 2.7: Line plot of the PDF total score in homology model (A) <i>PfPdx1</i> _MPD and (B) <i>PfPdx1</i> _Ru5P.	40
Figure 2.8: Ramachandran plots of <i>PfPdx1</i> _MPD (A) and <i>PfPdx1</i> _Ru5P (B).	41
Figure 2.9: Topology and homology model of <i>PfPdx1</i> _Ru5P.....	43
Figure 2.10: Overlay of <i>PfPdx1</i> with <i>PbPdx1</i>	44
Figure 2.11: Secondary structure diagram of minimised <i>PfPdx1</i> _MPD.....	46
Figure 2.12: Side view of <i>PfPdx1</i> _Ru5P superimposed on the <i>TmPdx1</i> template structure.	47
Figure 2.13: Ramachandran plots of <i>PfPdx1</i> homology models after protein minimisation.	48
Figure 2.14: The R5P-binding site of <i>PfPdx1</i> homology models.	50
Figure 2.15: Stereo view of the pharmacophores extracted from the <i>PfPdx1</i> homology models. 52	
Figure 2.16: Venn diagram representing the number of ligands identified from the respective <i>PfPdx1</i> pharmacophores.....	54
Figure 2.17: Complementary chemical features of ZINC03560463 that matched the <i>PfPdx1</i> _Ru5P pharmacophore.	55
Figure 2.18: Ligands mapped into the <i>PfPdx1</i> pharmacophore models using LPM.....	57
Figure 2.19: Structural pairwise similarity clustering of the best 50 pharmacophore-identified ligands by chemical similarity.....	58
Figure 2.20: The physiochemical properties of the best 277 LPM ligand hits.	60
Figure 2.21: Ligands docked in the <i>PfPdx1</i> _Ru5P homology model.	64
Figure 2.22: Compounds docked into <i>PbPdx1</i>	65
Figure 3.1: The Pdx1 reaction mechanism.....	75
Figure 3.2: SDS-PAGE and enzyme activity of purified <i>PfPdx1</i>	89
Figure 3.3: Effect of R5P-analogues on <i>PfPdx1</i> and I ₃₂₀ formation.	94
Figure 3.4: Inhibitory effect of E4P on <i>PfPdx1</i>	95
Figure 3.5: Detection of PLP is not affected by E4P.	96
Figure 3.6: Formation of R5P-related I ₃₂₀ with <i>PfPdx1</i> mutants.	98
Figure 3.7: E4P analogues and their effect on <i>PfPdx1</i>	100
Figure 3.8: Efficacy of 4PEHz and EHz against cultured <i>P. falciparum</i> (3D7) parasites.	102
Figure 3.9: Effects of 4PEHz on the proliferation of parasites complemented with <i>PfPdx1</i> / <i>PfPdx2</i> - and mock plasmids.	103
Figure 3.10: Effect of 4PEHz on the exponential growth of transgenic <i>P. falciparum</i>	104
Figure 4.1: Electropherogram of RNA isolated from untreated and 4PEHz-treated parasites. ..	125
Figure 4.2: Individual arrays from a single UT ₃ and Tt ₃ sample.	126
Figure 4.3: Boxplots of the log intensity (A) and log ratio expression (M) before and after array normalization.....	128
Figure 4.4: Density plots used to interpret array data before and after normalization.....	129
Figure 4.5: Volcanoplots generated for differently expressed transcripts affected by 4PEHz treatment.....	131

Figure 4.6: Differently expressed transcripts from UT _{t3} :Tt ₃ classified according to PlasmoDB predicted GO processes.	135
Figure 4.7: Functional annotation of differentially expressed transcripts using DAVID.	136
Figure 4.8: Transcripts which had significant expression and correlated between t ₁ (12HPI), t ₂ (24HPI) and t ₃ (36HPI).	137
Figure 4.9: GSEA analysis of Tt ₃ vs. UT _{t3}	144
Figure 4.10: Venn diagram of differentially expressed transcripts during t ₃ in 4PEHz-treated parasites.	146
Figure 4.11: Transcriptional responses of <i>P. falciparum</i> treated with 4PEHz compared to other parasite growth inhibitors.	148
Figure 4.12: 4PEHz treatment in t ₃ was shown to correlate with apicidin and staurosporine treatment of parasites.	149
Figure 4.13: Transcription factors affected by 4PEHz-treatment.	150
Figure 4.14: Real-time qRT-PCR validation of the t ₃ time point transcript expressions from microarrays.	151
Figure 4.15: SDS-PAGE of protein extracted from untreated and treated 4PEHz parasites at time point t ₃	153
Figure 4.16: Predicted interaction networks of <i>PfPdx1</i> and PLP.	155
Figure 4.17: Effect of 4PEHz on PLP-dependent enzyme transcripts as well as Pdx1-related transcripts.	161
Figure 5.1: Summary of the formation of PLP by <i>PfPdx1</i> and <i>PfPdx2</i> with inhibitors.	169

List of Tables

Table 1.1: Most widely used antimalarial therapeutics and resistance markers.	12
Table 1.2: PLP-dependent enzymes in <i>P. falciparum</i>	23
Table 2.1: Properties of homology models built using MODELER in DS.	39
Table 2.2: RMSD's of <i>PfPdx1</i> homology models.	42
Table 2.3: RMSD's of residues surrounding the R5P-binding site ligand in <i>PfPdx1</i> homology models.	42
Table 2.4: Properties of minimised <i>PfPdx1</i> homology models.	45
Table 2.5: RMSD's of minimised <i>PfPdx1</i> models.	47
Table 2.6: RMSD's of the R5P-binding site of minimised <i>PfPdx1</i> models.	49
Table 2.7: Summary of pharmacophore features identified from <i>PfPdx1</i> homology models.	51
Table 2.9: Ligands from the pharmacophore hits docked into <i>PfPdx1</i> models.	62
Table 3.1: Primers used in mutagenesis polymerase chain reactions (PCR) to create ΔC - and R164A <i>PfPdx1</i>	81
Table 3.2: Inhibitory activity of <i>in silico</i> identified compounds against <i>PfPdx1</i>	91
Table 3.3: Relative catalytic capabilities of <i>PfPdx1</i> variants.	99
Table 3.4: E4P analogues inhibit <i>PfPdx1</i>	101
Table 4.1: Parameters used for spot flagging and assessment in GenePix.	120
Table 4.2: Real-time qRT-PCR primers used to validate microarray data.	123
Table 4.3: Pearson correlations between UT and T array data of the 4PEHz treatment study. ...	130
Table 4.4: Twenty transcripts that showed the greatest differential decreased and increased abundance during 4PEHz treatment in t_3	133
Table 4.5: Differential expression of transcript in 4PEHz treated <i>P. falciparum</i> parasites.	139
Table 4.6: Transcripts associated with apicoplast fatty acid biosynthesis in <i>P. falciparum</i> affected by 4PEHz.	141
Table 4.7: Gene set enrichment analysis (GSEA) of Tt_3 compared to UTt_3	143
Table 4.8: Real-time PCR confirmation of microarray data.	152
Table 4.9: Summarized list of proteins identified in 4PEHz-treated parasites.	154
Table 4.10: Predicted interacting partners of <i>PfPdx1</i> (PFF1025c) and PLP.	156

Acknowledgements

My wife, Bianca Reeksting, for being so supportive, encouraging and understanding. Thank you for sacrificing so much, and enduring through the tough times.

My parents, Pearl and Bernard Reeksting, for their encouragement and support throughout my degree.

My supervisors, Prof. Carsten Wrenger and Prof. Lyn-Marie Birkholtz, as well as my co-supervisor Prof. Abraham Louw. You have been an inspiration and I am thankful for the guidance, patience and support you have provided to me.

Dr. Pieter B. Burger for help with computational approaches and drug libraries.

Dr. J. Knöckel for providing the *PfPdx1* and *PfPdx2* constructs. As well as the *PfPdx1/PfPdx2* overexpressing cell lines. Without your expertise this work would not have been possible.

Dr. Ingrid B. Müller at the Bernhard-Nocht Institute for Tropical Medicine (BNI) for providing the *PfPdx1* R164A mutant. Your insights into experimental design were really valuable to me, and I learnt a lot.

Mrs. Bärbel Bergmann for excellent experimental and technical assistance in the laboratory at the BNI.

The Biochemical Parasitology group at BNI for hosting and accommodating me in the laboratory, and always being keen for discussions over coffee.

Prof. Laurent Salmon for kindly providing R5P analogues.

Mrs. Janette Reader for her help in microarray experiments and data processing.

The DAAD for providing funding and giving me the opportunity to study in Germany.

The University of Pretoria for a postgraduate bursary.